The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Oxidative Stress in Parkinson's Disease: A Mechanism of Pathogenic and Therapeutic Significance
Open accessAbstract
Parkinson's disease (PD) is a common adult‐onset neurodegenerative disorder. Typically PD is a sporadic neurological disorder, and over time affected patients see their disability growing and their quality of life declining. Oxidative stress has been hypothesized to be linked to both the initiation and the progression of PD. Preclinical findings from both in vitro and in vivo experimental models of PD suggest that the neurodegenerative process starts with otherwise healthy neurons being hit by some etiological factors, which sets into motion a cascade of deleterious events. In these models initial molecular alterations in degenerating dopaminergic neurons include increased formation of reactive oxygen species, presumably originating from both inside and outside the mitochondria. In the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of PD, time‐course experiments suggest that oxidative stress is an early event that may directly kill some of the dopaminergic neurons. In this model it seems that oxidative stress may play a greater role in the demise of dopaminergic neurons indirectly by activating intracellular, cell death‐related, molecular pathways. As the neurodegenerative process evolves in the MPTP mouse model, indices of neuroinflammation develop, such as microglial activation. The latter increases the level of oxidative stress to which the neighboring compromised neurons are subjected to, thereby promoting their demise. However, these experimental studies have also shown that oxidative stress is not the sole deleterious factor implicated in the death of dopaminergic neurons. Should a similar multifactorial cascade underlie dopaminergic neuron degeneration in PD, then the optimal therapy for this disease may have to rely on a cocktail of agents, each targeting a different critical component of this hypothesized pathogenic cascade. If correct, this may be a reason why neuroprotective trials using a single agent, such as an antioxidant, have thus far generated disappointing results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
H 2 O 2 , a Necessary Evil for Cell Signaling
Rhee, S. G. (2006) · Science · doi:10.1126/science.1130481 · Cited by 2,160
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & -Y. Lee, V. M. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,546
Conway, K. A., Lee, S.-J., Rochet, J.-C., Ding, T. T., Williamson, R. E., & Lansbury, P. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.571 · Cited by 1,541
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Canet-Avilés, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M. J., Ringe, D., Petsko, G. A., & Cookson, M. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402959101 · Cited by 1,116
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Self-citationImmunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818
S -Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function
Chung, K. K. K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, V. L., & Dawson, T. M. (2004) · Science · doi:10.1126/science.1093891 · Cited by 769
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic
Zhou, Q.-Y., & Palmiter, R. D. (1995) · Cell · doi:10.1016/0092-8674(95)90145-0 · Cited by 731
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072550 · Cited by 637
Wu, D.-C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937239100 · Cited by 633
Self-citationInflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 625
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
Self-citationNitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
Self-citationAlam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031326.x · Cited by 547
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
Yao, D., Gu, Z., Nakamura, T., Shi, Z.-Q., Ma, Y., Gaston, B., Palmer, L. A., Rockenstein, E. M., Zhang, Z., Masliah, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404161101 · Cited by 515
Giasson, B. I., Uryu, K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7619 · Cited by 507
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase
Andres-Mateos, E., Perier, C., Zhang, L., Blanchard-Fillion, B., Greco, T. M., Thomas, B., Ko, H. S., Sasaki, M., Ischiropoulos, H., Przedborski, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703219104 · Cited by 479
Self-citationShults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra
Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb11759.x · Cited by 454
Floor, E., & Wetzel, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010268.x · Cited by 452
The Role of Glial Reaction and Inflammation in Parkinson's Disease
HIRSCH, E. C., BREIDERT, T., ROUSSELET, E., HUNOT, S., HARTMANN, A., & MICHEL, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 449
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426
Self-citationSchulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417
Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., & Ischiropoulos, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7659 · Cited by 414
Self-citationBrain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 402
Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology
Barrientos, A., & Moraes, C. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16188 · Cited by 383
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372
Self-citationAssays for 8-hydroxy-2′-deoxyguanosine: A biomarker of in vivo oxidative DNA damage
Shigenaga, M. K., & Ames, B. N. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90078-h · Cited by 364
Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase
Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359
Zhou, W., & Freed, C. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507124200 · Cited by 346
Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410420221 · Cited by 326
2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications
Kang, S. W., Rhee, S. G., Chang, T.-S., Jeong, W., & Choi, M. H. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.10.006 · Cited by 323
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 319
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
Perier, C., Tieu, K., Guégan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., & Vila, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508215102 · Cited by 308
Self-citationThe Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation
Lotharius, J., & O'Malley, K. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005385200 · Cited by 306
Glutathione peroxidase activity in Parkinson's disease brain
Kish, S. J., Morito, C., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 299
Oxidative damage in nucleic acids and Parkinson's disease
Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., & Sakumi, K. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21191 · Cited by 290
Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., Nunomura, A., Castellani, R. J., Perry, G., Smith, M. A., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0466 · Cited by 289
Functional Consequences of α-Synuclein Tyrosine Nitration
Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M.-Y., & Ischiropoulos, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408906200 · Cited by 286
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Pennathur, S., Jackson-Lewis, V., Przedborski, S., & Heinecke, J. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34621 · Cited by 265
Self-citationBeal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256
Genetic clues to the pathogenesis of Parkinson's disease
Vila, M., & Przedborski, S. (2004) · Nature Medicine · doi:10.1038/nm1068 · Cited by 255
Self-citationWu, D.-C., Ré, D. B., Nagai, M., Ischiropoulos, H., & Przedborski, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603670103 · Cited by 252
Self-citationRole of Cdk5-Mediated Phosphorylation of Prx2 in MPTP Toxicity and Parkinson's Disease
Qu, D., Rashidian, J., Mount, M. P., Aleyasin, H., Parsanejad, M., Lira, A., Haque, E., Zhang, Y., Callaghan, S., Daigle, M., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.033 · Cited by 251
Oxygen toxicity protecting enzymes in Parkinson's disease
Marttila, R. J., Lorentz, H., & Rinne, U. K. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90108-6 · Cited by 249
Meulener, M. C., Xu, K., Thomson, L., Ischiropoulos, H., & Bonini, N. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601891103 · Cited by 230
Perier, C., Bové, J., Wu, D.-C., Dehay, B., Choi, D.-K., Jackson-Lewis, V., Rathke-Hartlieb, S., Bouillet, P., Strasser, A., Schulz, J. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609874104 · Cited by 229
Self-citation(E)-4-Hydroxy-2-Nonenal May be Involved in the Pathogenesis of Parkinson’s Disease
Selley, M. L. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00021-5 · Cited by 215
Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction
Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S., & Chung, J. (2005) · Gene · doi:10.1016/j.gene.2005.06.040 · Cited by 213
Storch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205
Nigral and extranigral pathology in Parkinson's disease.
Braak, H., Braak, E., Yilmazer‐Hanke, D., Schultz, C., de Vos, R. A. I., & Jansen, E. N. H. (1995) · PubMed · Cited by 198
Antioxidants protect PINK1 -dependent dopaminergic neurons in Drosophila
Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W. S., Oldham, S., Xia, K., Wang, J., Bodmer, R., & Zhang, Z. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604661103 · Cited by 197
Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation
Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., & Fink, A. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608126200 · Cited by 191
Przedborski, S., Chen, Q., Vila, M., Giasson, B. I., Djaldatti, R., Vukosavic, S., Souza, J. M., Jackson‐Lewis, V., Lee, V. M. ‐., & Ischiropoulos, H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00174.x · Cited by 190
Self-citationSohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143
Mishizen-Eberz, A. J., Norris, E. H., Giasson, B. I., Hodara, R., Ischiropoulos, H., Lee, V. M. ‐., Trojanowski, J. Q., & Lynch, D. R. (2005) · Biochemistry · doi:10.1021/bi047846q · Cited by 119
Shults, C. W., Beal, M. F., Fontaine, D., Nakano, K., & Haas, R. (1998) · Neurology · doi:10.1212/wnl.50.3.793 · Cited by 116
Abe, T., Isobe, C., Murata, T., Sato, C., & Tohgi, H. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01259-4 · Cited by 107
Animal models of Parkinson’s disease in rodents induced by toxins: an update
Hirsch, É. C., Höglinger, G. U., Rousselet, E., Breidert, T., Parain, K., Féger, J., Ruberg, M., Prigent, A., Cohen‐Salmon, C., & Launay, J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_6 · Cited by 105
Rollema, H., Damsma, G., Horn, A. S., Vries, J. B. D., & Westerink, B. H. C. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90071-3 · Cited by 98
Iron‐sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease
Liang, L., & Patel, M. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02567.x · Cited by 95
Buhmann, C., Arlt, S., Kontush, A., Möller-Bertram, T., Sperber, S., Oechsner, M., Stuerenburg, H. J., & Beisiegel†, U. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.003 · Cited by 93
Lavara-Culebras, E., & Paricio, N. (2007) · Gene · doi:10.1016/j.gene.2007.06.013 · Cited by 92
Prigione, A., Begni, B., Galbussera, A., Beretta, S., Brighina, L., Garofalo, R., Andreoni, S., Piolti, R., & Ferrarese, C. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.013 · Cited by 80
Ramsay, R. R., & Singer, T. P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91523-s · Cited by 79
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
Perez, F. A., Curtis, W., & Palmiter, R. D. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-71 · Cited by 75
α‐tocopherol levels in brain are not altered in Parkinson's disease
Dexter, D. T., Jenner, P. G., Ward, R. J., Peter, T. J., Wells, F. R., Daniel, S. E., Lees, A. J., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320420 · Cited by 69
Neuroinflammation and Parkinson's disease
Przedborski, S. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83026-0 · Cited by 65
Self-citationModel fusion: The next phase in developing animal models for parkinson’s disease
Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 62
Clinical trials of coenzyme Q10 in neurological disorders
Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62
Moy, L. Y., Zeevalk, G. D., & Sonsalla, P. K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741656.x · Cited by 54
Hasbani, D. M., Perez, F. A., Palmiter, R. D., & O’Malley, K. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0130-05.2005 · Cited by 36
Superoxide Dismutase Expression in Parkinson's Disease
Poirier, J., Dea, D., Baccichet, A., & THIFFAUL, C. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21796.x · Cited by 31
How to judge animal models of Parkinson’s disease in terms of neuroprotection
Hirsch, É. C. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_39 · Cited by 17
Cited by
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Brain Energy and Oxygen Metabolism: Emerging Role in Normal Function and Disease
Watts, M. E., Pocock, R., & Claudianos, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00216 · Cited by 411
Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Rojo, A. I., Innamorato, N. G., Martín‐Moreno, A. M., De Ceballos, M. L., Yamamoto, M., & Cuadrado, A. (2010) · Glia · doi:10.1002/glia.20947 · Cited by 375
Gao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369
Niranjan, R. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8483-x · Cited by 327
Metadata
- Authors
- Zhou, C., Huang, Y., & Przedborski, S.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-12
- Volume
- 1147
- Issue
- 1
- Pages
- 93-104
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2333915371
- Cited by
- 450
- References
- 101
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.